Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

an open-label, non-comparative multi-center Phase 2 trial will have as its primary endpoint the partial or complete tumor response rate according to RECIST and/or GCIG guidelines. Secondary endpoints will include time to progression, survival, toxicity as well as adverse effects. The trial will include up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer). Patients will be administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours at a constant rate, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is six, three-week cycles. The planned study period is approximately 24 months. Further information on the trial is available at http://www.clinicaltrials.gov.

Prior Phase 1 trial results

On June 3, 2007 positive results of an open, multi-center, sequential group, dose-escalation Phase 1 study in various gynaecological cancers were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Illinois. 17 patients with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered by intravenous infusion over two hours at dosages of 10, 20, 40, 80, 160 and 267 mg/m2. At 160 mg/m2, six patients had a total of 32 cycles and at 267 mg/m2, seven patients had a total of 27 cycles. Most of the patients had been pretreated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in three out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZ
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... a definitive agreement with Novartis Pharma AG to acquire ... in Phase 3 development.  This agreement is conditional on the ... (GSK) on April 22, 2014, which are expected to close ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... Cardium Therapeutics (NYSE Amex: CXM ) today announced ... U.S. Food and Drug Administration (FDA) seeking marketing clearance ... XL is an advanced wound care management medical ... for use by physicians in patients with topical wounds, ...
... , BENLYSTA(TM) Successful in Second Pivotal Clinical Trial ... (HGS) and GlaxoSmithKline (GSK) today announced positive results from ... trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. ... shared at the 73rd Annual Scientific meeting of the ...
... , KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ ... ) announced today the U.S. Food and Drug ... to the company,s supplemental Biologics License Application regarding ... of patients with stage III malignant melanoma after ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 2U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 4U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 5U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 6
(Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... storage and use of surplus blood samples taken from newborns ... explicit to non-existent, leaving many parents ill-informed about how their ... team led by a member of the Johns Hopkins Berman ... of Utah. A report on their analysis of the subject ...
... Delhi, India The Indian Government today released new tiger ... numbers have increased in the country that has half of ... tiger numbers in India at 1,706, up from 1,411 during ... an additional tiger reserve in the count, the Sundarbans, that ...
... been the leaders in the use of intra-arterial yttrium-90 ... cancer. Now, new results from a large multi-institutional study ... Y-90 than previously tried is safe, provides results when ... can be done on an outpatient basis. This study, ...
Cached Biology News:Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4India releases tiger numbers as experts convene 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 3
...
...
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
...
Biology Products: